Glatiramer acetate treatment negatively regulates type I interferon signaling

OBJECTIVE: Glatiramer acetate (GA; Copaxone), a disease-modifying therapy for multiple sclerosis (MS), promotes development of anti-inflammatory (M2, type II) monocytes that can direct differentiation of regulatory T cells. We investigated the innate immune signaling pathways that participate in GA-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurol Neuroimmunol Neuroinflamm
Autors principals: Molnarfi, Nicolas, Prod'homme, Thomas, Schulze-Topphoff, Ulf, Spencer, Collin M., Weber, Martin S., Patarroyo, Juan C., Lalive, Patrice H., Zamvil, Scott S.
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4645172/
https://ncbi.nlm.nih.gov/pubmed/26601118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000179
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars